Misonix, Inc. (Misonix), a minimally invasive ultrasonic medical device company, has reported net sales of $39.8 million for the fiscal 2009, compared with the net sales of $41.14 million in the previous year-end. It also reported net income of $2.8 million or $0.40 per diluted share, for the fiscal 2009, compared with the net income of $2.9 million or $0.41 per diluted share, in the previous year-end.
Revenues for the fourth fiscal quarter ending June 30, 2009 were $10.5 million compared to $10.6 million for the three months ended June 30, 2008. The results reflect only continuing operations as of June 30, 2009 and 2008 as discontinued operations are excluded from such results. Discontinued operations represent the results of and the gain from the sale of the Ultrasonic Laboratory Products business. Revenues were adversely impacted by a reduction in medical device products revenues by $902,000 to $5.5 million, partially offset by an increase in Laboratory and Scientific products revenues of $811,000 to $4.9 million. The decrease in medical device products revenue is primarily due to lower sales of ultrasonic probe repairs, MRI repair, replacement probes and our AutoSonix product to Covidien. The increase in sales of Laboratory and Scientific products was primarily due to an increase in sales at Labcaire for ISIS product and service.
The company reported a net loss for the fourth quarter ended June 30, 2009 from continuing operations of $804,000 or $.11 per share compared to a loss from continuing operations of $2.4 million or $.35 per share for the three months ended June 30, 2008. During the fourth fiscal quarter 2009, the company sold its Ultrasonic Laboratory Products business to a subsidiary of Sonics and Materials Inc. for $3.5 million and reported an after tax gain of $2.7 million on the sale. The company reported net income including the income and the gain on sale from discontinued operations of $2.2 million or $0.31 income per diluted share for the three months ended June 30, 2009 as compared to a loss of $2.4 million or $0.34 per diluted share.
Medical device products revenues were $22.8 million as of June 30, 2009, a decrease of $1.5 million from the same period in fiscal 2008. Laboratory and Scientific products revenues were $17.0 million, an increase of $161,000 from the same period in fiscal 2008.